In the U.K. and Germany, we are the overwhelming market leaders in difficult burns as well as soft tissue reconstruction procedures. We hope to expand this leadership status across the remaining top 5 EU markets within the next eighteen months.
Given that Novosorb BTM had already achieved “market leader” status in UK and Germany a year ago, the 80+% growth in sales achieved in both countries in the year since is really impressive.
Now PNV’s aim is for BTM to become the market leader in France, Italy and Spain (combined population of 172m) over the next 18 months.
Ann: Appendix 4E and FY24 Financial Statements, page-37
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.61 |
Change
0.020(0.77%) |
Mkt cap ! $1.801B | |||
| Open | High | Low | Value | Volume |
| $2.59 | $2.62 | $2.56 | $2.442M | 940.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6098 | $2.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.62 | 193477 | 8 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| PNV (ASX) Chart |